Trial profile COJEC=cisplatin, carboplatin, cyclophosphamide,... | Download Scientific Diagram
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Neuroblastoma - Chung - 2021 - Pediatric Blood & Cancer - Wiley Online Library
LEXIPatho: Neuroblastome
Neuroblastoma | British Association of Paediatric Surgeons
Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
Treatment and management of newly diagnosed patients with high-risk neuroblastoma (not patients currently registered on HR-NBL-1
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial - The Lancet Oncology
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Schematic overview of therapy on SIOPEN/HR-NBL-1 and COG A3973. Rapid... | Download Scientific Diagram
Clinical impact of primary tumour 123ImIBG response to induction chemotherapy in children with high-risk neuroblastoma | International Journal of Clinical Oncology
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. - Abstract - Europe PMC
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy | Scientific Reports
![PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/61dfb3a5ee37540ef03aaa30a65508f621b16f2b/4-Table1-1.png "PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar")
PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
G-CSF counteracts chemotherapy toxicity in neuroblastoma - Document - Gale Academic OneFile
Browse Preprints - Authorea
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SI
Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv
Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study
